Know the usage and dosage of Eltrombopag/Eltrombopag, and scientific medication is guaranteed!

Eltrombopag is an oral thrombopoietin receptor agonist, mainly used to treat thrombocytopenia caused by immune system abnormalities, such as chronic immune thrombocytopenia (ITP), hepatitis C, severe aplastic anemia and other diseases. Eltrombopag stimulates the production of megakaryocytes in the bone marrow and promotes platelet synthesis, thereby effectively increasing the patient's platelet level and reducing the risk of bleeding. Scientific usage and dose adjustment are crucial to the therapeutic effect. This article will introduce the usage and dosage of eltrombopag in detail according to different patient groups to help patients use it rationally and ensure the efficacy.

1. Usage and dosage for patients with chronic immune thrombocytopenia (ITP)

For patients with chronic immune thrombocytopenia (ITP), the dose of eltrombopag should be individually adjusted based on the patient's specific condition. For non-Southeast Asian adults and children 6 years and older, the initial dose is 50 mg once daily, with the maximum daily dose being 75 mg. For patients of Southeast Asian descent, the initial dose should be halved to 25 mg once daily, and the maximum daily dose remains 75 mg.

In patients with impaired hepatic function, the dose of eltrombopag may require further adjustment. For patients with mild to severe hepatic impairment, the initial dose is 25 mg once daily, and the maximum daily dose is 75 mg. For patients of Southeast Asian descent with mild to severe liver impairment, the initial dose is lower, 12.5 mg once a day, and the maximum daily dose is 75 mg.

For pediatric patients 1-5 years of age, the initial dose is 25 mg once daily, with a maximum daily dose of 75 mg. It is important to note that with Eltrombopag, an increase in platelet count can usually be seen within 1-2 weeks after the start of treatment. Based on changes in platelet count, doctors may adjust the dose of the drug to maintain platelet count within the normal range.

2. Usage and dosage for patients with chronic hepatitis C

When treating patients with chronic hepatitis C, the initial dose of eltrombopag is usually 25 mg once daily. At the beginning of treatment, the doctor will increase the dose by 25mg every two weeks based on the patient's treatment response until the platelet level reaches the normal target. The maximum dose is 100 mg, which can be gradually increased to help patients gradually restore their platelet levels.

The treatment of patients with chronic hepatitis C requires close monitoring of blood routine and liver function to ensure the safety and efficacy of the drugs. During treatment, if adverse reactions or excessive platelet increases occur, the doctor will adjust the dose according to the patient's specific performance.

3. Usage and dosage for patients with severe aplastic anemia

For patients with severe aplastic anemia (SAA), the usage and dosage of eltrombopag vary according to the patient's age and condition. In patients 12 years of age and older, the initial dose is 150 mg once daily for 6 months. In pediatric patients 6 to 11 years of age, the initial dose is 75 mg once daily for 6 months. For pediatric patients aged 2 to 5 years old, the dose is calculated based on body weight. The initial dose is 2.5 mg/kg, once daily, and continued treatment for 6 months.

For patients of Southeast Asian descent and patients with mild to severe hepatic impairment, the above dosage needs to be reduced by half, and the starting dose will be adjusted appropriately based on the patient's liver function status. Patients with severe aplastic anemia need to regularly monitor blood routine and liver function during treatment to ensure the efficacy of the drug and detect potential adverse reactions in a timely manner.

4. Usage and dosage for patients with refractory severe aplastic anemia

For patients with refractory severe aplastic anemia (SAA), the therapeutic dose of eltrombopag is relatively low, with a starting dose of 50 mg once daily. This dose is suitable for most patients with refractory SAA, but patients' treatment response and platelet levels also need to be regularly evaluated. For patients of Southeast Asian descent or with mild to severe hepatic impairment, the initial dose is 25 mg once daily, with the maximum daily dose being 150 mg.xa0

During treatment, doctors will adjust the dose based on the patient's platelet levels and tolerance, and monitor possible changes in liver function. Patients with refractory SAA usually require long-term medication, so individualized adjustment of dosage is particularly important.

5. Precautions and monitoring requirements for taking eltrombopag

Eltrombopag should be used under the guidance of a physician. Patients need to regularly monitor platelet levels, liver function, blood routine and other indicators during the medication process in order to adjust the treatment plan in a timely manner. Because eltrombopag may affect liver function, patients with liver damage especially need to regularly check liver enzyme levels to ensure the safety of the drug.

Reference materials:https://go.drugbank.com/drugs/DB06210